ONLINE REGISTRATION IS NOW CLOSED. PLEASE REGISTER ON SITE FOR THE CONFERENCE AT THE SHERATON VALLEY FORGE.
Life Sciences Future, the largest annual gathering of the life sciences community on the east coast, is the conference for all stakeholders of the life sciences ecosystem - biopharma, medtech, academic research, hospitality, legal, financial, real estate communities and more. Conference features include partnering, plenary sessions of broad interest, and focused sessions on timely topics and speakers.
This conference will be the ultimate partnering event of the year - with opportunities for one-on-one partnering with the biggest names in the industry.
Olympic Gold Medalist, Cancer Survivor, Activist and Fundraiser
One of the most recognized male figure skating star in the world, Scott Hamilton has won 70 titles, awards and honors including an Emmy Award nomination, induction into the United States Olympic Hall of Fame and a privileged member of the World Figure Skating Hall of Fame.
After losing his mother to cancer, then becoming a survivor himself, Scott turned activist, launching the Scott Hamilton CARES Foundation (Cancer Alliance for Research, Education and Survivorship). The CARES Foundation collaborates with The V Foundation to invest in immunotherapy treatment for many types of cancer.
JAMES M. WILSON, MD, PhD
Director, Gene Therapy Program Professor of Medicine and Pediatrics, Perelman School of Medicine
Dr. James M. Wilson is a Professor in the Perelman School of Medicine at the University of Pennsylvania where he has led an effort to develop the field of gene therapy. His research career spanning over 40 years has focused on rare diseases and ways to treat them by gene therapy.
The Wilson Lab identified a new type of vector based on novel isolates of adeno-associated viruses which have become best in class for gene therapy. More recently Dr. Wilson’s laboratory has focused on improved vectors for gene therapy and clinical applications of genome editing and mRNA therapy.
DAVID FAJGENBAUM, MD, MBA, MSc, FCPP
Co-Founder & President
In 2010, Dr. David Fajgenbaum was diagnosed with Castleman Disease, and nearly died five times. He discovered a new use for an existing drug that had already been approved for another disease – but had never previously been used for Castleman Disease.
A 50-year-old patient battling life-threatening Castleman disease was provided adalimumab as a treatment of last resort following its identification by AI-guided discovery. Dr. Fajgenbaum assisted in the first usage of AI-discovered repurposed medicine and is dedicated to scaling this approach to help all patients who may benefit.
To view the full conference agenda, please visit the Life Sciences Future website.